VC
PSTX

Vivo Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Vivo Capital’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-926,447
Closed -$10.2M – 68
2020
Q4 		$10.2M Sell
926,447
-2
-0% -$21 0.45% 41
2020
Q3 		$8.22M Buy
+926,449
New +$10.5M 0.47% 43

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vivo Capital's PSTX Position: Q1 2021 in Review

Vivo Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2021, closing a stake of 926,447 shares — an estimated $10.2M sold.

Vivo Capital first reported a position in PSTX in Q3 2020 and held it in 2 quarters. The position peaked at $10.2M in Q4 2020. 62 funds tracked by Wall St. Rank hold PSTX as of Q1 2021.

  • Vivo Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Vivo Capital sold 926,447 Poseida Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $10.2M.
  • Vivo Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Vivo Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $10.2M in Q4 2020.
  • 62 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Vivo Capital's 13F filing for Q1 2021, filed 17 May 2021.